HPV16 E7(11-20)
Human papillomavirus type 16 E7 11-20 epitope
YMLDLQPETT Amino Acids · MW: 1210.37
Amino Acids
YMLDLQPETT
Molecular Weight
1210.37
Half-life
Minutes to hours; dependent on delivery system
Research Score
4.3
Studies
87
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is HPV16 E7(11-20)?
HPV16 E7(11-20) is a documented cytotoxic T-cell epitope derived from the HPV16 E7 oncoprotein. It has been used in therapeutic HPV vaccine research to stimulate epitope-specific cellular immunity.
Key Benefits & Mechanisms
viral tumor antigen epitope
induces HPV-specific CD8+ responses
relevant to therapeutic vaccine development
Research Summary
A real, literature-supported epitope used in HPV immunotherapy and vaccine platforms. It is commonly studied in peptide, nanoparticle, and dendritic-cell vaccine systems aimed at HPV-associated malignancies.
Related Peptides
PADRE
Pan HLA-DR-binding helper T-cell epitope
PADRE is a synthetic promiscuous CD4+ helper T-cell epitope designed to bind many HLA-DR alleles. It is widely used in peptide vaccine research to improve helper T-cell priming and strengthen responses to linked antigens.
Vaccine PeptidesSIINFEKL
Ovalbumin 257-264 epitope (SIINFEKL)
SIINFEKL is a classic MHC class I epitope derived from chicken ovalbumin. It is one of the most widely used model peptides for studying antigen presentation, cytotoxic T-cell priming, and peptide vaccine platforms.
Vaccine PeptidesAAGIGILTV
MART-1/Melan-A 26-35 epitope
AAGIGILTV is a well-known HLA-A2-restricted epitope from the melanocyte differentiation antigen MART-1/Melan-A. It has been studied in melanoma vaccine research to generate antigen-specific T-cell responses against tumor cells.
Vaccine PeptidesWT1-126_134
Wilms Tumor 1 (WT1) peptide epitope RMFPNAPYL (aa 126-134)
A canonical HLA-A*0201-restricted WT1 peptide used in leukemia and solid-tumor vaccine studies. It is designed to elicit WT1-specific cytotoxic T cells against overexpressing tumor cells.
Vaccine Peptides